J Finkelstein - Regenerx Biopharm CEO and President and Director
| RGRXDelisted Stock | USD 0.0009 0.0001 12.50% |
CEO
Mr. J. J. Finkelstein is President, Chief Executive Officer, Director of the Company. Mr. Finkelstein also served as our Chief Executive Officer from 1984 to 1989 and as the Vice Chairman of our Board of Directors from 1989 to 1991. Mr. Finkelstein has worked as an executive officer and consultant in the bioscience industry for the past 36 years, including serving from 1989 to 1996 as chief executive officer of Cryomedical Sciences, Inc., a publiclytraded medical device company. Mr. Finkelstein has significant experience in developing earlystage companies. He was responsible for the regulatory approval and marketing of several medical devices in the U.S. and abroad. Mr. Finkelstein has previously served on the executive committee of the Board of Directors of the Technology Council of Maryland and MdBio, Inc. and currently chairs the MdBio Foundation, all of which are nonprofit entities that support bioscience development and education in the State of Maryland. Mr. Finkelstein received a business degree in finance from the University of Texas. The Board believes that Mr. Finkelsteins history and long tenure as our Chief Executive Officer positions him to contribute to the Board his extensive knowledge of our company and to provide Board continuity. In addition, the Board believes that his experience at prior companies has provided him with operational and industry expertise, as well as leadership skills that are important to the Board. since 2002.
| Age | 71 |
| Tenure | 22 years |
| Phone | 301 208 9191 |
| Web | https://www.regenerx.com |
Regenerx Biopharm Management Efficiency
The company has return on total asset (ROA) of (0.8397) % which means that it has lost $0.8397 on every $100 spent on assets. This is way below average. Regenerx Biopharm's management efficiency ratios could be used to measure how well Regenerx Biopharm manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.14 M in liabilities. Regenerx Biopharm has a current ratio of 1.03, suggesting that it may have difficulties to pay its financial obligations when due. Debt can assist Regenerx Biopharm until it has trouble settling it off, either with new capital or with free cash flow. So, Regenerx Biopharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regenerx Biopharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regenerx to invest in growth at high rates of return. When we think about Regenerx Biopharm's use of debt, we should always consider it together with cash and equity.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. REGENERX BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people. Regenerx Biopharm In [RGRX] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Regenerx Biopharm is listed under Pharmaceutical Products category by Fama And French industry classification. Management Performance
| Return On Asset | -0.84 |
Regenerx Biopharm Leadership Team
Elected by the shareholders, the Regenerx Biopharm's board of directors comprises two types of representatives: Regenerx Biopharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regenerx. The board's role is to monitor Regenerx Biopharm's management team and ensure that shareholders' interests are well served. Regenerx Biopharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regenerx Biopharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| J Finkelstein, CEO and President and Director | ||
| Nabila Turjman, Ex Affairs | ||
| Don Elsey, Independent Director | ||
| Allan Goldstein, Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board | ||
| Alessandro Noseda, Director | ||
| Joseph McNay, Independent Director | ||
| Raymond Elsey, Independent Director | ||
| Mauro Bove, Independent Director |
Regenerx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Regenerx Biopharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.84 | ||||
| Operating Margin | (19.03) % | ||||
| Current Valuation | 22.91 M | ||||
| Shares Outstanding | 143.55 M | ||||
| Shares Owned By Insiders | 45.99 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 19.19 K | ||||
| Price To Earning | 17.73 X | ||||
| Price To Sales | 261.81 X | ||||
| Revenue | 76.76 K |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |